Allogene Therapeutics, Inc. (ALLO) News
Track canonical SquawkNews coverage tagged to ALLO, Allogene Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Allo Files $500M Mixed Shelf Offering
Allo files $500,000,000 mixed shelf offering
EQUITY | Aug 12, 2026, 08:24 PM UTC
L
Allogene Therapeutics Reports Q2 2026 Results
Allogene Therapeutics reports second quarter 2026 financial results and business update
EARNINGS | Aug 12, 2026, 08:05 PM UTC
L
ALLO - Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
ALLO - Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
EARNINGS | Aug 04, 2026, 12:30 PM UTC
H
Allogene: No Serious Adverse Events For Cema-Cel
Allogene reports no serious adverse events for cema-cel
EQUITY | Jul 29, 2026, 12:36 PM UTC
L
ALLO Allogene Therapeutics receives FDA regenerative Medicine advanced therapy (rmat) designation for cemacabtagene ansegedleucel (cema-cel)
ALLO Allogene Therapeutics receives FDA regenerative Medicine advanced therapy (rmat) designation for cemacabtagene ansegedleucel (cema-cel) as first-line consolidation therapy for large B-cell lymphoma
REGULATION | Jul 29, 2026, 12:30 PM UTC
L
ALLO Journal of Clinical Oncology Publication of Phase 1 Results of ALLO 316 Highlighting First Durable Remissions Following Allogeneic Car
ALLO Journal of Clinical Oncology Publication of Phase 1 Results of ALLO 316 Highlighting First Durable Remissions Following Allogeneic Car T for Treatment of Metastatic Solid Tumors
EQUITY | Jul 15, 2026, 01:30 PM UTC